It's official: Abbott Laboratories' (NYSE:ABT) board of directors has approved the company's spinoff of its pharmaceuticals division to form the new company, AbbVie. The approval was expected, of course, but the announcement has given investors some much-awaited details regarding how AbbVie shares will be distributed among current shareholders. In this video, Motley Fool health care analyst Brenton Flynn tells us what the distribution will be, when it's going to take place, and when to make sure you either buy Abbott or sell -- if you'd like to be a part of the transition or avoid it altogether. Also, he discusses what we can expect the stock to do when the first of the year comes -- and why it will be nothing to worry about.


This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.